Healthcare Roundup—Leadership changes at Press Ganey; Mount Sinai invests in meal-delivery service

Press Ganey names new CEO, Patrick Ryan assumes executive chairman title 

Patrick Ryan has assumed a growth-focused role as executive chairman at Press Ganey, the consulting firm announced on Thursday. 

Ryan, who served as Press Ganey’s CEO from 2012, will still lead the firm, but his work will now center on expansion and identifying investment opportunities. Joe Greskoviak, Press Ganey’s chief operating officer, will take on the CEO role and oversee day-to-day operations. 

Greskoviak will report to Ryan; the two have worked together for more than a decade. 

“This new leadership structure will effectively position Press Ganey for the next phase of our growth and for the dynamic changes we hope to drive as an industry,” Ryan said. (Announcement

Mount Sinai makes third investment in food-delivery company Epicured 

Mount Sinai Ventures, the investment arm of Mount Sinai Health System, announced it would make a third investment in food-delivery company Epicured. 

Epicured offers a menu tailored to patients with digestive diseases. The estimated 20% to 30% of the population with conditions like Crohn’s disease, irritable bowel syndrome and colitis can manage the illnesses with a tailored diet. 

Brent Stackhouse, managing director and vice president of Mount Sinai Ventures, said access to Epicured can have an immediate impact on patients. 

“We see a lot of investment in the ‘food as medicine’ movement,” he said in a release. “Epicured is a great addition to our portfolio and demonstrates our commitment to innovative solutions in population health and investment opportunities that move the mission of the Mount Sinai Health System forward.” (Announcement

NorthShore partners with genetic testing firm Color on DNA10K initiative 

NorthShore University HealthSystem has joined forces with genetic testing firm Color to offer genome sequencing to 10,000 of its primary care patients. 

The DNA10K initiative is an expansion of a pilot between NorthShore and Color that led to 1,000 sign-ups for genetic tests. NorthShore hopes that the genomic screenings could lead to more personalized care and flag risks for improved disease prevention. 

Patients that participate in the program will also have access to genetic counselors and clinical pharmacists who can explain the results and develop individualized prevention plans. (Announcement